Arbovirus Testing Market Size Worth $1.98 Billion By 2034 | CAGR: 4.70%

The global arbovirus testing market size is expected to reach USD 1.98 billion by 2034, according to a new study by Polaris Market Research. The report “Arbovirus Testing Market Share, Size, Trends, Industry Analysis Report, By Test Type (ELISA-based Tests, RT-PCR based Tests, and Others); By Arboviral Disease; By End-use; By Region; Segment Forecast, 2025- 2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The primary drivers propelling the growth of the arbovirus testing market are the rising number of patients infected with arthropod-borne viral infections and the growing number of government programs aimed at controlling the burden of arboviral diseases. For instance, according to the data from the European Centre for Disease Prevention and Control, in 2023, the number of chikungunya cases in Brazil and Paraguay were 256,927 and 140,905, respectively. Moreover, the growing cases of West Nile Virus infections in countries such as the U.S., coupled with an increased focus on government activities to promote the advantages of early testing, are expected to boost the market growth in the upcoming years.

The increased risk of arboviral diseases that people of tropical and subtropical regions experience due to warm temperatures and high humidity will be beneficial for the market expansion. Moreover, the high priority of governments on funding, allocation of resources, and establishment of programs for managing the burden of arboviral diseases drives market growth. Furthermore, rising cases of yellow fever, dengue, and chikungunya in developing countries contribute to market growth. For instance, according to the European Centre for Disease Prevention and Control’s data, in 2023, the number of chikungunya cases in the Philippines was 2,561. Such a large patient pool from developing countries will provide an opportunity for the growth of the arbovirus testing market during the forecast timeframe.

Do you have any questions? Would you like to request a sample or make an inquiry before purchasing this report? Simply click the link below: Download Sample Report

The main causes for the rising incidence of arboviral infections include urbanization, climate change, and greater travel of people and goods. Moreover, the climatic changes leading to high temperatures and humidity increase the risk of spread of the dengue epidemic, thereby fueling the demand for arbovirus tests. Furthermore, market players prioritizing the introduction of new products coupled with a rise in research and development expenditures for rapid tests are expected to foster the arbovirus testing market growth in the projected years.    

Arbovirus Testing Market Report Highlights

• The ELISA-based tests segment generated the largest revenue share of 44.8% in 2025. This is due to technological advancements in ELISA testing.
• The dengue segment held a considerable market share of 51.3% in 2025. The presence of a large patient pool suffering from dengue globally contributes to market demand in this segment.
• The public health laboratories segment dominated with a 46.2% share in 2025. This is owing to strong government funding and active outbreak surveillance.
• North America led with a 39.4% revenue share in 2025. The rising burden of neglected tropical diseases (NTDs) and the growing incidence of West Nile virus drive the regional market dominance.
• Asia Pacific is anticipated to register the highest 5.4% CAGR. The growing patient population suffering from various arboviral diseases contributes to the regional market growth.
• The market players include Agilent Technologies Inc., Thermo Fisher Scientific, NovaTec Immundiagnostica GmbH, Euroimmun AG, Abbott, etc.

Polaris Market Research has segmented the arbovirus testing market report based on test type, arboviral disease, end-use, and region:

Arbovirus Testing, Test Type Outlook (Revenue - USD Billion, 2021 - 2034)

• ELISA-based Tests
• RT-PCR based Tests
• Others

Arbovirus Testing, Arboviral Disease Outlook (Revenue - USD Billion, 2021 - 2034)

• Dengue
• Yellow Fever
• Zika Virus
• West Nile Virus
• Chikungunya 
• Others

Arbovirus Testing, End-use Outlook (Revenue - USD Billion, 2021 - 2034)

• Hospitals
• Diagnostic Centers
• Public Health Laboratories
• Others

Arbovirus Testing, Regional Outlook (Revenue - USD Billion, 2021 - 2034)

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Australia
  • Malaysia
  • Rest of Asia Pacific
• Latin America
  • Argentina
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa
  • Rest of Middle East & Africa